GlassScriptPhysician profile
Michael M Babinski
NPI 1699362020
$2,240.43
in general payments reported to CMS, 2019-2025
35 companies · $924 in 2025
The $924 reported for 2025 was more than what 83% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $92.09 · 2023: $561 · 2024: $663 · 2025: $924.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,131 · Debt Forgiveness: $17.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,130.84 |
| Debt Forgiveness | $17.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $306.22 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $214.15 | 2022-2025 | |
| Lilly USA, LLC | $155.44 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Phathom Pharmaceuticals, INC. | $148.24 | 2024 | Voquezna |
| Novo Nordisk INC | $142.29 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Medtronic, INC. | $137.80 | 2024-2025 | Inceptiv, Intellis Adaptivestim |
| Pfizer INC. | $107.20 | 2023-2025 | |
| Axsome Therapeutics, INC. | $99.79 | 2025 | Symbravo |
| Corcept Therapeutics | $79.99 | 2025 | Korlym |
| Otsuka America Pharmaceutical, INC. | $73.81 | 2023-2025 | Rexulti |
| Amgen INC. | $73.76 | 2024-2025 | Otezla, Repatha, Repatha |
| Astellas Pharma US INC | $57.84 | 2024-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $57.35 | 2024-2025 | Spravato |
| Depuy Synthes Sales INC. | $48.92 | 2024 | Peak, Monovisc, Orthovisc |
| Azurity Pharmaceuticals, INC. | $47.22 | 2024-2025 | Azmiro, Horizant |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $44.26 | 2022 | |
| Esperion Therapeutics, INC. | $44.03 | 2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $36.34 | 2023-2025 | |
| Valinor Pharma, LLC | $34.99 | 2024 | Movantik |
| Antares Pharma, INC. | $34.75 | 2025 | Xyosted |
| Verity Pharmaceuticals INC. | $34.02 | 2025 | Tlando |
| Novartis Pharmaceuticals Corporation | $29.74 | 2022-2023 | |
| Mirum Pharmaceuticals, INC. | $24.40 | 2024 | Cholbam |
| Neos Therapeutics, LP | $21.92 | 2023 | Adzenys Xr-Odt |
| Merck Sharp & Dohme LLC | $21.79 | 2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.86 | 2024 | Jardiance |
| Lundbeck LLC | $18.56 | 2023 | Rexulti |
| Baxter Healthcare | $17.50 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.05 | 2023 | Xifaxan |
| Currax Pharmaceuticals LLC | $16.10 | 2022 | |
| Sumitomo Pharma America, INC. | $16.05 | 2023 | Gemtesa |
| Glaxosmithkline, LLC. | $14.87 | 2025 | Trelegy Ellipta |
| Eisai INC. | $14.80 | 2025 | |
| Bioventus LLC | $14.48 | 2025 | Xcell |
| Ferring Pharmaceuticals INC. | $13.90 | 2025 | Euflexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Babinski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.